Alpha Cognition Inc(ACOG) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.12 | Insider Own | 8.56% | Shs Outstand | 21.8M | Perf Week | -3.37% |
| Market Cap | 0.19B | Forward P/E | - | EPS next Y | 53.22% | Insider Trans | 53.62% | Shs Float | 14.2M | Perf Month | -0.56% |
| Enterprise Value | 0.15B | PEG | - | EPS next Q | -0.34 | Inst Own | 76.42% | Short Float | 1.49% | Perf Quarter | 47.35% |
| Income | -0.02B | P/S | 12.7 | EPS this Y | -12.68% | Inst Trans | -2.64% | Short Ratio | 1.97 | Perf Half Y | 52.14% |
| Sales | 0.02B | P/B | 3.66 | EPS next 5Y | - | ROA | -42.76% | Short Interest | 0.21M | Perf YTD | 36.92% |
| Book/sh | 2.43 | P/C | 4.68 | EPS past 3/5Y | 35.73% 45.28% | ROE | -55.25% | 52W High | -12.23% ($10.14) | Perf Year | -9% |
| Cash/sh | 1.9 | P/FCF | - | Sales past 3/5Y | - | ROIC | -44.26% | 52W Low | 97.78% ($4.50) | Perf 3Y | 22.76% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 31.08% | Gross Margin | 89.24% | Volatility(W/M) | 5.67% 7.12% | Perf 5Y | -72.34% |
| Dividend TTM | - | EV/Sales | 9.99 | Sales Y/Y TTM | 232.74% | Oper. Margin | -190.62% | ATR (14) | 0.62 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8 | EPS Q/Q | 38.34% | Profit Margin | -153.61% | RSI (14) | 47.31 | Recom | 1.2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9 | Sales Q/Q | 267.56% | SMA20 | -3.85% ($9.26) | Beta | 2.23 | Target Price | $18 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/13 | SMA50 | 1.57% ($8.76) | Rel Volume | 0.8 | Prev Close | $8.9 |
| Employees | 71 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -2.01% 36.86% | SMA200 | 33.43% ($6.67) | Avg Volume(3M) | 0.11M | Price | $8.9 |
| IPO | 2021/6/28 | Option/Short | Yes/Yes | Trades | 632 | Volume | 85,329 | Change | - |
Company
ACOG is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
Alpha Cognition is a pharmaceutical company developing treatments for neurodegenerative diseases, including Alzheimer's dementia and ALS (amyotrophic lateral sclerosis). Headquartered in Vancouver, Canada, the company has entered the commercialization stage after receiving U.S. Food and Drug Administration (FDA) approval for its oral tablet formulation of an Alzheimer's treatment. As a small-cap biopharmaceutical company, it is focused on expanding its neuroscience pipeline.
Over the past 1 year, on the higher side
12% below its 1-year high.
ACOG has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -12.7% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +22.8% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 76.4%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $194M.
ACOG $194M PER -
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is ACOG?
ACOG belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ACOG?
The market cap of ACOG is approximately $194M, ranking 4,152 within its sector.
What is the 52-week high and low for ACOG?
ACOG has recorded a 52-week high of $10.14 and a low of $4.50.
